Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis

BACKGROUND: Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have demonstrated promise in treating a variety of advanced cancers; however, little is known regarding their efficacy under various clinical situations, including different cancer types, treatment lines, drug combinations, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shixue, Zhang, Zhibo, Zheng, Xuan, Tao, Haitao, Zhang, Sujie, Ma, Junxun, Liu, Zhefeng, Wang, Jinliang, Qian, Yuanyu, Cui, Pengfei, Huang, Di, Huang, Ziwei, Wu, Zhaozhen, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085334/
https://www.ncbi.nlm.nih.gov/pubmed/33937012
http://dx.doi.org/10.3389/fonc.2021.562315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085334/
https://www.ncbi.nlm.nih.gov/pubmed/33937012
http://dx.doi.org/10.3389/fonc.2021.562315

Ejemplares similares